Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSE2101 + FOLFIRI Maintenance in PDAC
NCT03806309Phase 2Active, not recruiting
- Sponsor
- GERCOR
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Tedopi in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by GERCOR. Primary endpoint: Overall Survival at 12 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
Tedopi
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03806309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806309.